tbuckley/cabot-search huggingface dataset:
RIVAROXABAN REDUCES HOSPITALIZATIONS FOR THROMBOEMBOLIC EVENTS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE AFTER REVASCULARIZATION IN THOSE WITH AND WITHOUT CHRONIC KIDNEY DISEASE
Authors: Mark Svet, Judith A. Hsia, Manesh R. Patel, Sonia Anand, E. Sebastian Debus, Mark Nehler, Connie Ng Hess, Warren Capell, Eva Muehlhofer, Lloyd Haskell, Scott D. Berkowitz, Rupert Bauersachs, Marc P. Bonaca
Journal: Journal of the American College of Cardiology (2022)
NCCN News
Authors: A Saad, Alison Loren
Journal: Journal of the National Comprehensive Cancer Network (2022)

NCCN has announced the publication of new NCCN Guidelines for Patients: Graft-Versus-Host Disease (GVHD).GVHD is a complication that occurs after a donor stem cell or bone marrow (ie, hematopoietic) transplant-which is used to cure some types of blood cancers.One goal of donor hematopoietic cell transplants is for the donor's immune cells to attack the cancerous cells, an important contributor to achieving a cure.When GVHD occurs, the transplanted donor cells attack the patient's healthy body tissues, causing mild or severe symptoms.Incidences of acute and chronic GVHD continue to be significant in the United States, in particular with the increasing use of incompletely matched donors-meaning the healthy cells are donated from a someone who is not a perfect tissue-type (also known as HLA) match. 1 "GVHD is a transplant complication that comes as a surprise for many patients," said Susan Stewart, Executive Director, BMT InfoNet and 32-year bone marrow transplant survivor."It can significantly impact a patient's quality of life, particularly if it persists long-term.Knowing the symptoms, so that it can be caught early-as well as potential treatment options-is crucial for GVHD patients.""Anyone who undergoes stem cell transplantation from a donor should be aware of the possibility of acute or chronic GVHD, which arises when the donor immune cells see host tissues as foreign, and attack them," said Ayman
Treatment of Ligneous Conjunctivitis with Plasminogen Eyedrops
Authors: Roberto Caputo, Amy D. Shapiro, Maria Teresa Sartori, Andrea Leonardi, Bennie H. Jeng, Charles Nakar, Irene Di Pasquale, Francis W. Price, Neelam Thukral, Anna Lotti Suffredini, Laura Pino, Roberto Crea, Prasad Mathew, Mirella Calcinai
Journal: Ophthalmology (2022)
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a<scp>post‐hoc</scp>analysis of the<scp>ATHENA</scp>trial
Authors: Muthiah Vaduganathan, Jonathan P. Piccini, A. John Camm, Harry J.G.M. Crijns, Stefan D. Anker, Javed Butler, John Stewart, Rogelio Braceras, Alessandro P.A. Albuquerque, Mattias Wieloch, Stefan H. Hohnloser
Journal: European Journal of Heart Failure (2022)

Limited therapeutic options are available for the management of atrial fibrillation/flutter (AF/AFL) with concomitant heart failure (HF) with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF). Dronedarone reduces the risk of cardiovascular events in patients with AF, but sparse data are available examining its role in patients with AF complicated by HFpEF and HFmrEF.ATHENA was an international, multicentre trial that randomized 4628 patients with paroxysmal or persistent AF/AFL and cardiovascular risk factors to dronedarone 400 mg twice daily versus placebo. We evaluated patients with (i) symptomatic HFpEF and HFmrEF (defined as left ventricular ejection fraction [LVEF] >40%, evidence of structural heart disease, and New York Heart Association class II/III or diuretic use), (ii) HF with reduced ejection fraction (HFrEF) or left ventricular dysfunction (LVEF ≤40%), and (iii) those without HF. We assessed effects of dronedarone versus placebo on death or cardiovascular hospitalization (primary endpoint), other key efficacy endpoints, and safety. Overall, 534 (12%) had HFpEF or HFmrEF, 422 (9%) had HFrEF or left ventricular dysfunction, and 3672 (79%) did not have HF. Patients with HFpEF and HFmrEF had a mean age of 73 ± 9 years, 37% were women, and had a mean LVEF of 57 ± 9%. Over a mean follow-up of 21 ± 5 months, dronedarone consistently reduced risk of death or cardiovascular hospitalization (hazard ratio 0.76; 95% confidence interval 0.69-0.84) without heterogeneity based on HF status (pinteraction >0.10). This risk reduction in the primary endpoint was consistent across the range of LVEF (as a continuous function) in HF without heterogeneity (pinteraction = 0.71). Rates of death, cardiovascular hospitalization, and HF hospitalization each directionally favoured dronedarone versus placebo in HFpEF and HFmrEF, but these treatment effects were not statistically significant in this subgroup.Dronedarone is associated with reduced cardiovascular events in patients with paroxysmal or persistent AF/AFL and HF across the spectrum of LVEF, including among those with HFpEF and HFmrEF. These data support a rationale for a future dedicated and powered clinical trial to affirm the net clinical benefit of dronedarone in this population.
PROGRESSION OF CHA2DS2-VASC LEADS TO INCREASED STROKE RISK IN ATRIAL FIBRILLATION
Authors: Brennan Lanier, Abdel Hadi El Hajjar, Mario Mekhael, Charbel Noujaim, Hogan K. Hudgins, Christopher Pottle, Lilas Dagher, Nassir F. Marrouche
Journal: Journal of the American College of Cardiology (2022)
Co-evolution of machine learning and digital technologies to improve monitoring of Parkinson’s disease motor symptoms
Authors: Anirudha S. Chandrabhatla, I. Jonathan Pomeraniec, Alexander Ksendzovsky
Journal: npj Digital Medicine (2022)

Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor impairments such as tremor, bradykinesia, dyskinesia, and gait abnormalities. Current protocols assess PD symptoms during clinic visits and can be subjective. Patient diaries can help clinicians evaluate at-home symptoms, but can be incomplete or inaccurate. Therefore, researchers have developed in-home automated methods to monitor PD symptoms to enable data-driven PD diagnosis and management. We queried the US National Library of Medicine PubMed database to analyze the progression of the technologies and computational/machine learning methods used to monitor common motor PD symptoms. A sub-set of roughly 12,000 papers was reviewed that best characterized the machine learning and technology timelines that manifested from reviewing the literature. The technology used to monitor PD motor symptoms has advanced significantly in the past five decades. Early monitoring began with in-lab devices such as needle-based EMG, transitioned to in-lab accelerometers/gyroscopes, then to wearable accelerometers/gyroscopes, and finally to phone and mobile & web application-based in-home monitoring. Significant progress has also been made with respect to the use of machine learning algorithms to classify PD patients. Using data from different devices (e.g., video cameras, phone-based accelerometers), researchers have designed neural network and non-neural network-based machine learning algorithms to categorize PD patients across tremor, gait, bradykinesia, and dyskinesia. The five-decade co-evolution of technology and computational techniques used to monitor PD motor symptoms has driven significant progress that is enabling the shift from in-lab/clinic to in-home monitoring of PD symptoms.
DECISION TREE MODEL FOR PREDICTING CORONARY CARE UNIT RESOURCE USE IN LATINAMERICAN PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE MYOCARDIAL; A MACHINE LEARNING APPLICATION
Authors: Juan Felipe Vasquez, Cruz-Gutierrez Nelson Alirio, Ramirez-Lovera Valeria, Idrovo-Turbay Carolina, Alberto Navarro, Medina-Mur Ramon, Luis Giraldo, Ariza Nicolas, Isaza-Restrepo Daniel
Journal: Journal of the American College of Cardiology (2022)
GENDER DISPARITY IN OUTCOMES OF PATIENTS UNDERGOING LEFT ATRIAL APPENDAGE OCCLUSION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Chol Techorueangwiwat, Chanavuth Kanitsoraphan, Jason Kuniyoshi, Todd Nagamine, Parthav Shah, Somsupha Kanjanauthai
Journal: Journal of the American College of Cardiology (2022)
Hepatic recruitment of eosinophils and their protective function during acute liver injury
Authors: Long Xu, Yang Yang, Yankai Wen, Jong-Min Jeong, Christoph Emontzpohl, Constance L. Atkins, Zhaoli Sun, Kyle L. Poulsen, David R. Hall, J. Steve Bynon, Bin Gao, William M. Lee, Jody Rule, Elizabeth A. Jacobsen, Hua Wang, Cynthia Ju
Journal: Journal of Hepatology (2022)
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer
Authors: Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, David Stenehjem
Journal: Journal of the National Comprehensive Cancer Network (2022)
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
Authors: Chunfeng Li, Audrey Lee, Lilit Grigoryan, Prabhu S. Arunachalam, Madeleine K. D. Scott, Meera Trisal, Florian Wimmers, Mrinmoy Sanyal, Payton A. Weidenbacher, Yupeng Feng, Julia Z. Adamska, Erika Valore, Yanli Wang, Rohit Verma, Noah Reis, Diane Dunham, Ruth O’Hara, Helen Park, Wei Luo, Alexander D. Gitlin, Peter Kim, Purvesh Khatri, Kari C. Nadeau, Bali Pulendran
Journal: Nature Immunology (2022)
FINANCIAL TOXICITY AND PATIENT-REPORTED ECONOMIC BURDEN IN PATIENTS WITH ATTR: RESULTS FROM AMYLOIDOSIS RESEARCH CONSORTIUM’S ATTR TREATMENT AFFORDABILITY PATIENT AND CAREGIVER SURVEY
Authors: Sabrina Rebello, Kristen Hsu, Jose Nativi-Nicolau, Chafic Karam, Martha Grogan, Isabelle Lousada, Mathew S. Maurer
Journal: Journal of the American College of Cardiology (2022)
EXTRACORONARY VASCULAR ABNORMALITIES IN PATIENTS WITH SPONTANEOUS CORONARY ARTERY DISSECTION: A REPORT OF THE ISCAD REGISTRY
Authors: Soo Hyun Kim, Malissa J. Wood, Anna Grodzinsky, Heather L. Gornik, Bryan J. Wells, Daniella Kadian-Dodov, Aditya M. Sharma, Connie Ng Hess, Jennifer Lewey, Stanislav Henkin, Gretchen L. Wells, Lori Tam, Clara Vitarello, Fahad Alkhalfan, Gerald Chi, C. Michael Gibson, Katherine Leon, Sahar Naderi
Journal: Journal of the American College of Cardiology (2022)
RANDOMIZED CLINICAL TRIAL ON PREVENTION OF RADIAL ARTERY OCCLUSION AFTER TRANSRADIAL ACCESS USING NITROGLYCERIN
Authors: Roberto Leo da Silva, Pedro B. de Andrade, Alexandre Abizaid, Rodrigo De Moura Joaquim, Thais RW da Silva, Ramiro Grazziotin Vieira, Vanderlei C. Pereira, Amanda G.M.R. Sousa, Fausto Feres, Jose de Ribamar Costa
Journal: Journal of the American College of Cardiology (2022)
Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge
Authors: Jennifer M. Polinski, Andrew R. Weckstein, Michael Batech, Carly Kabelac, Tripthi Kamath, Raymond Harvey, Sid Jain, Jeremy A. Rassen, Najat Khan, Sebastian Schneeweiss
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Vaccination against the SARS-CoV-2 virus is critical to control the pandemic. Randomized clinical trials demonstrated efficacy of the single-dose Ad26.COV2.S COVID-19 vaccine, but data on longer-term protection in clinical practice and effectiveness against variants are needed. <h3>Objective</h3> To assess the association between receiving the Ad26.COV2.S vaccine and COVID-19–related infections and hospitalizations before and during the Delta variant surge. <h3>Design, Setting, and Participants</h3> This cohort study included adults aged 18 years and older who were newly Ad26.COV2.S-vaccinated matched to as many as 10 unvaccinated individuals by date, location, age, sex, and comorbidity index. This was followed by 1:4 propensity score matching on COVID-19 risk factors. Data were collected from US insurance claims data from March 1, 2020, through August 31, 2021. <h3>Exposures</h3> Vaccination with Ad26.COV2.S vs no vaccination. <h3>Main Outcomes and Measures</h3> Vaccine effectiveness (VE) was estimated for recorded COVID-19 infection and COVID-19–related hospitalization, nationwide and in subgroups by age, high-risk factors, calendar time, and states with high incidences of the Delta variant. VE estimates were corrected for underrecording of vaccinations in insurance data. <h3>Results</h3> Among 422 034 vaccinated individuals (mean [SD] age, 54.7 [17.4] years; 236 437 [56.0%] women) and 1 645 397 matched unvaccinated individuals (mean [SD] age, 54.5 [17.5] years; 922 937 [56.1%] women), VE was 76% (95% CI, 75%-77%) for COVID-19 infections and 81% (95% CI, 78%-82%) for COVID-19–related hospitalizations. VE was stable for at least 180 days after vaccination and over calendar time. Among states with high Delta variant incidence, VE during June to August 2021 was 74% (95% CI, 71%-77%) for infections and 81% (95% CI, 75%-86%) for hospitalizations. VE for COVID-19 was higher in individuals younger than 65 years (78%; 95% CI, 77%-79%) and lower in immunocompromised patients (64%; 95% CI, 59%-68%). All estimates were corrected for vaccination underrecording; uncorrected VE, which served as a lower bound, was 66% (95% CI, 64%-67%) for any recorded COVID-19 infection and 72% (95% CI, 69%-74%) for COVID-19–related hospitalization. <h3>Conclusions and Relevance</h3> This cohort study in US clinical practice showed stable VE of Ad26.COV2.S for at least 6 months before as well as during the time the Delta variant emerged and became dominant.
PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
Authors: Julie Delyon, Lucie Biard, Marion Renaud, Matthieu Resche-Rigon, Jérôme Le Goff, Stéphane Dalle, Valentine Heidelberger, Laetitia Da Meda, Laurie Toullec, Guislaine Carcelain, Samia Mourah, Sophie Caillat-Zucman, Vincent Allain, Maxime Battistella, Céleste Lebbe
Journal: The Lancet Oncology (2022)
Human dendritic cells in cancer
Authors: Egle Kvedaraite, Florent Ginhoux
Journal: Science Immunology (2022)

Dendritic cells (DCs) are professional antigen-presenting cells, orchestrating innate and adaptive immunity during infections, autoimmune diseases, and malignancies. Since the discovery of DCs almost 50 years ago, our understanding of their biology in humans has increased substantially. Here, we review both antitumor and tolerogenic DC responses in cancer and discuss lineage-specific contributions by their functionally specialized subsets, including the conventional DC (cDC) subsets cDC1 and cDC2, the newly described DC3, and the plasmacytoid DCs (pDCs), focusing on the human setting. In addition, we review the lineage-unrestricted "mature DCs enriched in immunoregulatory molecules" (mregDC) state recently described across different human tumors.
Deep learning-enabled coronary CT angiography for plaque and stenosis quantification and cardiac risk prediction: an international multicentre study
Authors: Andrew Lin, Nipun Manral, Priscilla McElhinney, Aditya Killekar, Hidenari Matsumoto, Jacek Kwiecinski, Konrad Pieszko, Aryabod Razipour, Kajetan Grodecki, Caroline Park, Yuka Otaki, Mhairi Doris, Alan C Kwan, Donghee Han, Keiichiro Kuronuma, Guadalupe Flores Tomasino, Evangelos Tzolos, Aakash Shanbhag, Markus Goeller, Mohamed Marwan, Heidi Gransar, Balaji K Tamarappoo, Sebastien Cadet, Stephan Achenbach, Stephen J Nicholls, Dennis T Wong, Daniel S Berman, Marc Dweck, David E Newby, Michelle C Williams, Piotr J Slomka, Damini Dey
Journal: The Lancet Digital Health (2022)

Atherosclerotic plaque quantification from coronary CT angiography (CCTA) enables accurate assessment of coronary artery disease burden and prognosis. We sought to develop and validate a deep learning system for CCTA-derived measures of plaque volume and stenosis severity.
IN-HOSPITAL COMPLICATIONS AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION AMONG PATIENTS WITH AND WITHOUT SARCOIDOSIS: A PROPENSITY-MATCHED ANALYSIS
Authors: Alexander Dang, Steven Mai, Marcus Ynalvez, Mohamad Khaled Soufi, Ayman Elbadawi, Christopher M. Nguyen, Michelle Baliss, Rafic F. Berbarie, Wissam Khalife
Journal: Journal of the American College of Cardiology (2022)
PREVALENCE OF LIGHT-CHAIN AMYLOIDOSIS AMONG PATIENTS REFERRED FOR TECHNETIUM-99M PYROPHOSPHATE IMAGING: A COMMUNITY-BASED MULTI-CENTER STUDY
Authors: Rabah Alreshq, Steven R. Sigman, Arman Seth, Catherine Marti, Andrew Thomas Darlington, Arun Krishnamoorthy, Frederick L. Ruberg
Journal: Journal of the American College of Cardiology (2022)
Recipient and Donor Outcomes After Living-Donor Liver Transplant for Unresectable Colorectal Liver Metastases
Authors: Roberto Hernandez-Alejandro, Luis I. Ruffolo, Kazunari Sasaki, Koji Tomiyama, Mark S. Orloff, Karen Pineda-Solis, Amit Nair, Jennie Errigo, M. Katherine Dokus, Mark Cattral, Ian D. McGilvray, Anand Ghanekar, Steven Gallinger, Nazia Selzner, Marco P. A. W. Claasen, Ron Burkes, Koji Hashimoto, Masato Fujiki, Cristiano Quintini, Bassam N. Estfan, Choon Hyuck David Kwon, K. V. Narayanan Menon, Federico Aucejo, Gonzalo Sapisochin
Journal: JAMA Surgery (2022)

Colorectal cancer is a leading cause of cancer-related death, and nearly 70% of patients with this cancer have unresectable colorectal cancer liver metastases (CRLMs). Compared with chemotherapy, liver transplant has been reported to improve survival in patients with CRLMs, but in North America, liver allograft shortages make the use of deceased-donor allografts for this indication problematic.To examine survival outcomes of living-donor liver transplant (LDLT) for unresectable, liver-confined CRLMs.This prospective cohort study included patients at 3 North American liver transplant centers with established LDLT programs, 2 in the US and 1 in Canada. Patients with liver-confined, unresectable CRLMs who had demonstrated sustained disease control on oncologic therapy met the inclusion criteria for LDLT. Patients included in this study underwent an LDLT between July 2017 and October 2020 and were followed up until May 1, 2021.Living-donor liver transplant.Perioperative morbidity and mortality of treated patients and donors, assessed by univariate statistics, and 1.5-year Kaplan-Meier estimates of recurrence-free and overall survival for transplant recipients.Of 91 evaluated patients, 10 (11%) underwent LDLT (6 [60%] male; median age, 45 years [range, 35-58 years]). Among the 10 living donors, 7 (70%) were male, and the median age was 40.5 years (range, 27-50 years). Kaplan-Meier estimates for recurrence-free and overall survival at 1.5 years after LDLT were 62% and 100%, respectively. Perioperative morbidity for both donors and recipients was consistent with established standards (Clavien-Dindo complications among recipients: 3 [10%] had none, 3 [30%] had grade II, and 4 [40%] had grade III; donors: 5 [50%] had none, 4 [40%] had grade I, and 1 had grade III).This study's findings of recurrence-free and overall survival rates suggest that select patients with unresectable, liver-confined CRLMs may benefit from total hepatectomy and LDLT.
Acute Kidney Injury Associates with Long-Term Increases in Plasma TNFR1, TNFR2, and KIM-1: Findings from the CRIC Study
Authors: Ian E. McCoy, Jesse Y. Hsu, Joseph V. Bonventre, Chirag R. Parikh, Alan S. Go, Kathleen D. Liu, Ana C. Ricardo, Anand Srivastava, Debbie L. Cohen, Jiang He, Jing Chen, Panduranga S. Rao, Chi-yuan Hsu
Journal: Journal of the American Society of Nephrology (2022)

Some markers of inflammation-TNF receptors 1 and 2 (TNFR1 and TNFR2)-are independently associated with progressive CKD, as is a marker of proximal tubule injury, kidney injury molecule 1 (KIM-1). However, whether an episode of hospitalized AKI may cause long-term changes in these biomarkers is unknown.
RACIAL AND SOCIOECONOMIC HEALTH DISPARITY ASSOCIATED WITH POOR OUTCOMES IN NEONATAL AND PEDIATRIC CARDIAC SURGERY: MULTI-CENTERED, CROSS-SECTIONAL STUDY USING THE RISK ADJUSTMENT FOR CONGENITAL HEART SURGERY-2 (RACHS-2) WITHIN THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS)
Authors: Shaun Setty, Lauren Reynolds, Vanessa Chou, Maya Yu, Stephen Kang, Philip Allen, Lan Tran, Jennifer Le
Journal: Journal of the American College of Cardiology (2022)
A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia
Authors: Fei Kong, Hongliang He, Huiyuan Bai, Fang Yang, Ming Ma, Ning Gu, Yu Zhang
Journal: Bioactive Materials (2022)

Despite the progress made to improve therapeutic outcomes for acute myeloid leukemia (AML), many unmet clinical needs remain to be resolved. Unlike existing anti-AML strategies, here we developed a biomimetic nanocomposite to efficiently eliminate the leukemia cells in the bone marrow and prevent the homing of AML. To fulfill our design, the ultra-small nanozyme was conjugated onto the surface of an oxygen-carrying nanoparticle, which was further coated with bone marrow stromal cell membrane. After entering the blood, this biomimetic nanocomposite got actively internalized by the leukemia cells in the blood and released the loaded chemotherapeutics and nanozyme inside the leukemia cells to achieve a synergistic antitumor efficacy. Meanwhile, the adhesive properties of the stromal cell membrane enabled the nanocomposite to home to the bone marrow, where the nanocomposite effectively killed the retained leukemia cells. More importantly, the biomimetic cell membrane also acted as a CXCR4 antagonism to block the CXCR4/CXCL12-mediated homing of leukemia cells to the bone marrow and infiltration to other organs like the liver and spleen. In conclusion, this proof-of-concept study demonstrated that our designed platform effectively kills leukemia cells while preventing their infiltration, thus providing a promising prospect for resolving the clinical challenges in current AML treatment.
“BEHIND THE EIGHT BALL”: LEFT VENTRICULAR ASSIST DEVICE PLACEMENT IN A PATIENT WITH LEFT VENTRICULAR THROMBUS AND CRITICAL CARDIOGENIC SHOCK
Authors: Vanessa Hurtado, Jorge Penalver, Nicole Parellada, Sherif Roman, Milena Benitez, Marian Calfa
Journal: Journal of the American College of Cardiology (2022)
An Unusual False-Positive Uptake of Radioiodine Caused by Breast Implants
Authors: Yu Wang, Lisha Jiang, Yangmengyuan Xu, Xinyue Zhang, Bin Liu
Journal: Clinical Nuclear Medicine (2022)

Abstract A 40-year-old woman with a history of papillary thyroid cancer underwent ablative 131 I therapy. Postablation whole-body 131 I scintigraphy revealed not only increased activity in the thyroid bed but also in the anterior part of the chest. SPECT/CT images localized the activity in the bilateral breast implants.
PRIMARY PREVENTION OF SUDDEN DEATH WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IN PATIENTS WITH DILATED CARDIOMYOPATHY OF CHAGASIC ETIOLOGY
Authors: Sergio Velasco, Guillermo Mora Pabon, Jorge Alberto Cortes, Mayra Guarnizo, Alejandro Olaya, andres diaz
Journal: Journal of the American College of Cardiology (2022)
Joint Pain in a Woman Wearing a Face Mask
Authors: Jason E. Liebowitz, Maximilian F. Konig
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal